Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Hannah Farmer, Nuala McCabe, Christopher J. Lord et al. · Nature · 2005 · 6.7K citations

Life Sciences, Genetics, Molecular Biology +16

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cherrie K. Donawho, Yan Luo, Yanping Luo et al. · Clinical Cancer Research · 2007 · 773 citations · Full text

Medicine, Oncology, Pharmacology +15

PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase

Jean‐Christophe Amé, Véronique Rolli, Valérie Schreiber et al. · Journal of Biological Chemistry · 1999 · 748 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +14

4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1

Keith Menear, Claire Adcock, Robert Boulter et al. · Journal of Medicinal Chemistry · 2008 · 586 citations · Full text

Medicine, Oncology, Pharmacology +16

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

Yuqiao Shen, Farah Rehman, Ying Feng et al. · Clinical Cancer Research · 2013 · 487 citations · Full text

Medicine, Oncology, Pharmacology +14